Beth Y. Karlan, MD
- The doctor practices in an office or specialty that we currently do not survey.
- The doctor has not yet received the minimum number of patient satisfaction surveys (30) to be eligible for display.
- The doctor practices in an office or specialty that we currently do not survey.
- The doctor has not yet received the minimum number of patient satisfaction surveys (30) to be eligible for display.
Languages
- English,
Gender
Female
Experience
41 Years
Locations
Beverly Hills
34.0662882 -118.4085184Beverly Hills
Experience
Specialties
Area in which a healthcare provider is highly trained and often board certified.
1
- OB GYN-Oncology
Research Areas
Titles
- Board of Governors Chair in Gynecologic Oncology
- Director, Women's Cancer Program in the Samuel Oschin Comprehensive Cancer Institute
- Director, Division of Gynecologic Oncology
- Director, Gilda Radner Hereditary Cancer Program
- Professor, Obstetrics and Gynecology
Education & Training
-
UCLA Medical Center
Fellowship - Completed 1989
-
Yale-New Haven Hospital
Residency - Completed 1986
-
Yale-New Haven Hospital
Internship - Completed 1983
-
Harvard Medical School
Medical School - Completed 1982
Achievements
-
2
Board Certifications
-
7
Awards and Honors
Board Certifications
-
Obstetrics & Gynecology
American Board of Obstetrics and Gynecology
-
Gynecologic Oncology
American Board of Obstetrics and Gynecology
Awards and Honors
- Distinguished Service Award, Society of Gynecologic Oncology — recognizing achievements as Editor-in-Chief of Gynecologic Oncology Journal and Gynecologic Oncology Reports
- Clinical Research Professorship: American Cancer Society
- Prize for Excellence in Ovarian Cancer Research, Gynecologic Cancer Foundation
- Editor-in-Chief: Gynecologic Oncology
- Claudia Cohen Research Foundation Prize for Outstanding Cancer Researcher
- Member, National Cancer Advisory Board
- Board of Governors Chair in Gynecologic Oncology
Publications
- Karlan BY, Thorpe J, Watabayashi K, Drescher CW, Palomares M, Daly MB, Paley P, Hillard P, Andersen MR, Anderson G, et al. Use of CA125 and HE4 serum markers to predict ovarian cancer in elevated-risk women. Cancer Epidemiol Biomarkers Prev. 2014;23(7):1383-1393.
- Karlan BY, Dering J, Walsh C, Orsulic S, Lester J, Anderson LA, Ginther CL, Fejzo M, Slamon D. POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer. Gynecol Oncol. 2014;132(2):334-342.
- Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian cancer mortality. Nature. 2011;474(7353):609-15.
- Karlan BY, Oza AM, Richardson GE, Provencher DM, Hansen VL, Buck M, Chambers SK, Ghatage P, Pippitt CH Jr, Brown JV 3rd, et al. Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J Clin Oncol. 2011;30(4):362-371.